{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:55:42Z","timestamp":1790931342759,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00259-026-08029-4","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T02:01:12Z","timestamp":1782871272000},"page":"6870-6880","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic value of [18F]FDG PET\/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-8197-1023","authenticated-orcid":false,"given":"Juliette","family":"Frega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"8029_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"8029_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","volume":"401","author":"SA Hurvitz","year":"2023","unstructured":"Hurvitz SA, Hegg R, Chung W-P, Im S-A, Jacot W, Ganju V, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401:105\u201317. https:\/\/doi.org\/10.1016\/S0140-6736(22)02420-5.","journal-title":"Lancet"},{"key":"8029_CR3","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab Deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2407086.","journal-title":"N Engl J Med"},{"key":"8029_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"8029_CR5","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S1470-2045(17)30604-6","volume":"18","author":"T Doi","year":"2017","unstructured":"Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, et al. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody\u2013drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017;18:1512\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30604-6.","journal-title":"Lancet Oncol"},{"key":"8029_CR6","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1200\/JCO.2014.60.0353","volume":"33","author":"NU Lin","year":"2015","unstructured":"Lin NU, Guo H, Yap JT, Mayer IA, Falkson CI, Hobday TJ, et al. Phase II study of Lapatinib in combination with Trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: clinical outcomes and predictive value of early [18F]Fluorodeoxyglucose positron emission tomography imaging (TBCRC 003). J Clin Oncol. 2015;33:2623\u201331. https:\/\/doi.org\/10.1200\/JCO.2014.60.0353.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8029_CR7","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40644-023-00608-0","volume":"23","author":"G Ma","year":"2023","unstructured":"Ma G, You S, Xie Y, Gu B, Liu C, Hu X, et al. Pretreatment 18F-FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer. Cancer Imaging. 2023;23:90. https:\/\/doi.org\/10.1186\/s40644-023-00608-0.","journal-title":"Cancer Imaging"},{"key":"8029_CR8","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2967\/jnumed.121.263358","volume":"64","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Harbo F, Jakobsen NM, Nissen HJ, Dahlsgaard-Wallenius SE, Gerke O, et al. Response monitoring in metastatic breast cancer: a prospective study comparing 18F-FDG PET\/CT with conventional CT. J Nucl Med. 2023;64:355\u201361. https:\/\/doi.org\/10.2967\/jnumed.121.263358.","journal-title":"J Nucl Med"},{"key":"8029_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1193174","author":"A Annovazzi","year":"2023","unstructured":"Annovazzi A, Rea S, Maccora D, Pizzuti L, Ferretti G, Vici P, et al. Prognostic value of [18F]-FDG PET\/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors. Front Oncol. 2023. https:\/\/doi.org\/10.3389\/fonc.2023.1193174.","journal-title":"Front Oncol"},{"key":"8029_CR10","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1002\/cncr.27579","volume":"118","author":"PG Morris","year":"2012","unstructured":"Morris PG, Ulaner GA, Eaton A, Fazio M, Jhaveri K, Patil S, et al. Standardized uptake value by positron emission tomography\/computed tomography as a prognostic variable in metastatic breast cancer. Cancer. 2012;118:5454\u201362. https:\/\/doi.org\/10.1002\/cncr.27579.","journal-title":"Cancer"},{"key":"8029_CR11","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1007\/s00259-024-06696-9","volume":"51","author":"SC Vaz","year":"2024","unstructured":"Vaz SC, Woll JPP, Cardoso F, Groheux D, Cook GJR, Ulaner GA, et al. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET\/CT in no special type breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:2706\u201332. https:\/\/doi.org\/10.1007\/s00259-024-06696-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8029_CR12","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annpat.2021.07.014","volume":"41","author":"C Franchet","year":"2021","unstructured":"Franchet C, Djerroudi L, Maran-Gonzalez A, Abramovici O, Antoine M, Becette V, et al. Mise \u00e0 jour 2021\u00a0des recommandations du GEFPICS pour l\u2019\u00e9valuation du statut HER2\u00a0dans les cancers infiltrants du sein en France. Ann Pathol. 2021;41:507\u201320. https:\/\/doi.org\/10.1016\/j.annpat.2021.07.014.","journal-title":"Ann Pathol"},{"key":"8029_CR13","doi-asserted-by":"publisher","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","volume":"50","author":"RL Wahl","year":"2009","unstructured":"Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med Off Publ Soc Nucl Med. 2009;50:122S-50S. https:\/\/doi.org\/10.2967\/jnumed.108.057307.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"8029_CR14","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s00259-014-2739-1","volume":"41","author":"O Humbert","year":"2014","unstructured":"Humbert O, Cochet A, Riedinger J-M, Berriolo-Riedinger A, Arnould L, Coudert B, et al. HER2-positive breast cancer: 18F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1525\u201333. https:\/\/doi.org\/10.1007\/s00259-014-2739-1.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8029_CR15","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1007\/s00259-024-06929-x","volume":"52","author":"R-D Seban","year":"2025","unstructured":"Seban R-D, Champion L, De Moura A, Lerebours F, Loirat D, Pierga J-Y, et al. Pre-treatment [18F]FDG PET\/CT biomarkers for the prediction of antibody-drug conjugates efficacy in metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2025;52:708\u201318. https:\/\/doi.org\/10.1007\/s00259-024-06929-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8029_CR16","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.clcc.2025.01.006","volume":"24","author":"C Zwarthoed","year":"2025","unstructured":"Zwarthoed C, Jaraudias C, Evesque L, Baron D, Fran\u00e7ois E, Chardin D, et al. Prognostic values of pre- and post-therapeutic FDG-PET in anal canal cancer: analysis of a prospective study. Clin Colorectal Cancer. 2025;24:256-263.e8. https:\/\/doi.org\/10.1016\/j.clcc.2025.01.006.","journal-title":"Clin Colorectal Cancer"},{"key":"8029_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2021.110107","volume":"146","author":"G Schweighofer-Zwink","year":"2022","unstructured":"Schweighofer-Zwink G, Manafi-Farid R, K\u00f6lblinger P, Hehenwarter L, Harsini S, Pirich C, et al. Prognostic value of 2-[18F]FDG PET-CT in metastatic melanoma patients receiving immunotherapy. Eur J Radiol. 2022;146:110107. https:\/\/doi.org\/10.1016\/j.ejrad.2021.110107.","journal-title":"Eur J Radiol"},{"key":"8029_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/RLU.0b013e3182816318","volume":"38","author":"J Zhang","year":"2013","unstructured":"Zhang J, Jia Z, Zhou M, Ragaz J, Zhang Y-P, Wang B-Y, et al. The SUVmax for (18)F-FDG correlates with molecular subtype and survival of previously untreated metastatic breast cancer. Clin Nucl Med. 2013;38:256\u201362. https:\/\/doi.org\/10.1097\/RLU.0b013e3182816318.","journal-title":"Clin Nucl Med"},{"key":"8029_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112824","volume":"13","author":"E Agostinetto","year":"2021","unstructured":"Agostinetto E, Rediti M, Fimereli D, Debien V, Piccart M, Aftimos P, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers (Basel). 2021;13:2824. https:\/\/doi.org\/10.3390\/cancers13112824.","journal-title":"Cancers (Basel)"},{"key":"8029_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113314","volume":"12","author":"M Sirico","year":"2020","unstructured":"Sirico M, Bernocchi O, Sobhani N, Giudici F, Corona SP, Vernieri C, et al. Early changes of the standardized uptake values (SUVmax) predict the efficacy of everolimus-exemestane in patients with hormone receptor-positive metastatic breast cancer. Cancers (Basel). 2020;12:3314. https:\/\/doi.org\/10.3390\/cancers12113314.","journal-title":"Cancers (Basel)"},{"key":"8029_CR21","unstructured":"Kitajima K, Higuchi T, Yamakado K, Miyoshi Y. Early assessment of tumor response using 18F-FDG PET\/CT after one cycle of systemic therapy in patients with recurrent and metastatic breast cancer."},{"key":"8029_CR22","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.2967\/jnumed.115.166629","volume":"57","author":"K Pinker","year":"2016","unstructured":"Pinker K, Riedl CC, Ong L, Jochelson M, Ulaner GA, McArthur H, et al. The impact that number of analyzed metastatic breast cancer lesions has on response assessment by 18F-FDG PET\/CT using PERCIST. J Nucl Med. 2016;57:1102\u20134. https:\/\/doi.org\/10.2967\/jnumed.115.166629.","journal-title":"J Nucl Med"},{"key":"8029_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-32727-w","volume":"13","author":"M Vogsen","year":"2023","unstructured":"Vogsen M, Naghavi-Behzad M, Harbo FG, Jakobsen NM, Gerke O, Asmussen JT, et al. 2-[18F]FDG-PET\/CT is a better predictor of survival than conventional CT: a prospective study of response monitoring in metastatic breast cancer. Sci Rep. 2023;13:5552. https:\/\/doi.org\/10.1038\/s41598-023-32727-w.","journal-title":"Sci Rep"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08029-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08029-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T08:32:08Z","timestamp":1790929928000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08029-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8029"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08029-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki and was approved by local Institutional Review Board (Faculty of Medicine\/Strasbourg University Hospitals, IRB 2024-22).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that human research participants provided informed consent for publication of the images in Figure 3.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}